

HLA typing in cancer




Human Leukocyte Antigen (HLA) is a highly polymorphic region composed of several genes involved in immune regulation. HLA typing is the characterization of this set of genes and is a valuable tool for targeting recurrent mutations and hotspot sites implicated in cancer pathogenesis. This method is also used to match donor and patient before solid organ or allogeneic stem cell transplants, often used to treat cancers such as leukemia, lymphoma, multiple myeloma, and neuroblastoma. Next-Generation Sequencing (NGS) is the latest technology used to perform HLA typing, offering better precision at a lower cost than traditional techniques such as LD PCR (Hosomichi et al. 2015). NGS in the HLA typing context requires specificity, fidelity, and robustness to work with a wide range of complex DNA templates. We offer high-quality and high-performance tools for HLA typing, including high-fidelity polymerases for targeted sequencing and NGS library preparation kits.

Highlighted products

Our [PrimeSTAR GXL](#) and [Takara LA Taq](#) DNA polymerases have been shown to be ideal enzymes for HLA typing via targeted sequencing (NGS and Sanger) due to their high fidelity, ability to robustly amplify long fragments, and GC-rich-template tolerance. Indeed, a number of publications have cited the use of PrimeSTAR GXL and/or *LA Taq* enzymes for HLA typing (Liu et al. 2018; Xu, Wang, and Hong 2017; Yin et al. 2016; Mayor et al. 2011; Lan et al. 2015; Ozaki et al. 2013; Ozaki et al. 2015), and both Anthony Nolan and NHSBT (London, United Kingdom) are routinely using these enzymes for HLA typing.

In addition, our [SMARTer PicoPLEX WGA](#) and [SMARTer PicoPLEX Gold Single Cell DNA-seq](#) kits allow robust whole genome amplification (downstream applications: HLA typing via NGS, Sanger, or array), even from single cells (Murphy et al. 2016; Png et al. 2011). [SMARTer PicoPLEX Gold technology](#) (Figure 1) allows robust and reproducible whole genome amplification from single cells with a streamlined and straightforward workflow. [SMARTer ThruPLEX DNA-Seq kits](#) can also be used for NGS library preparation.






Figure 1. SMARTer PicoPLEX Gold Single Cell DNA-Seq technology. Panel A. Schematic depicting the simple, four-step PicoPLEX Gold workflow with minimum hands-on time. **Panel B.** Schematic illustrating the PicoPLEX Gold chemistry. Cellular gDNA extracted in Step 1 is used as the template for multiple cycles of quasi-random priming and linear amplification followed by exponential library amplification.

References and product citations

- Hosomichi, K. *et al.* The impact of next-generation sequencing technologies on HLA research. *J. Hum. Genet.* **60**, 665–673 (2015).
- Lan, J. H. *et al.* Impact of three Illumina library construction methods on GC bias and HLA genotype calling. *Hum. Immunol.* **76**, 166–175 (2015).
- Liu, C. *et al.* Accurate typing of human leukocyte antigen class I genes by oxford nanopore sequencing. *J. Mol. Diagn.* **2**, 006 (2018).
- Mayor, N. P. *et al.* HLA typing for the next generation. *PLOS ONE* **10**, e0127153 (2015).
- Murphy, N. M. *et al.* Haplotyping the human leukocyte antigen system from single chromosomes. *Sci. Rep.* **6**, 30381 (2016).
- Png, E. *et al.* A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. *Hum. Mol. Genet.* **20**, 3893–3898 (2011).
- Ozaki, Y. *et al.* HLA-DRB1, -DRB3, -DRB4 and -DRB5 genotyping at a super-high resolution level by long-range PCR and high-throughput sequencing. *Tissue Antigens* **83**, 10–16 (2013).
- Ozaki, Y. *et al.* Cost-efficient multiplex PCR for routine genotyping of up to nine classical HLA loci in a single analytical run of multiple samples by next-generation sequencing. *BMC Genomics* **16**, 318 (2015).
- Xu, Y.-P., Wang, S.-X. & Hong, W.-X. A novel HLA-E allele, *HLA-E*01:01:01:06*, identified in a Chinese Leukemia patient. *HLA* **89**, 260–262 (2017).
- Yin, Y. *et al.* Application of high-throughput next-generation sequencing for HLA typing on buccal extracted DNA: results from over 10,000 donor recruitment samples. *PLoS One* **11**, e0165810 (2016).

Takara Bio USA, Inc.

United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2023 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.